Boston Scientific (NYSE:BSX) is reportedly still considering a market withdrawal in India for its Synergy adsorbable polymer stent, after repeated attempts to lift a government-imposed price cap were rebuffed by regulators there. Representatives from the Marlborough, Mass.-based medical device giant met yesterday with National Pharmaceutical Pricing Authority officials to discuss pulling Synergy from India, according to LiveMint. […]
Indian National Pharmaceutical Pricing Authority (NPPA)
India’s NPPA says it will not revisit stent price caps until Feb 2018
India’s National Pharmaceutical Pricing Authority said today it won’t be revising its cap on coronary stents, applied earlier this year, until Feb. 2018, according to a LiveMint report. The regulatory body for India established price caps earlier this year that cut prices on coronary stents by over 80%, causing major players in the region to […]
India regulator wants price caps on more coronary, peripheral devices
Indian healthcare regulators reportedly reversed course and are now asking for a quartet of medical devices to be added to a list of products under price control. India’s National Pharmaceutical Pricing Authority wants its list of price-capped products updated to include balloon and cardiac catheters, covered stents and peripheral stents, Reuters reported. If the government there approves, they […]
India’s NPPA to audit hospitals on claims of stent overcharging
India’s National Pharmaceutical Pricing Authority is initiating an audit of all angioplasty cases at several hospitals and medical institutions in the country after receiving complaints of overcharging for stents, according to an Indian Express report. The NPPA’s audit will focus on hospitals that have “inconclusively” responded to the organization, according to the report. “Hospitals have […]
Medtronic, Abbott could still seek exit from India’s high-end stent market
Updated to include extra information on company plans for the market. Medtronic (NYSE:MDT) and Abbott (NYSE:ABT) could take another run at taking their high-end stents off the Indian market, after the Indian National Pharmaceutical Pricing Authority this week rejected their applications to withdraw. Abbott, Boston Scientific and Johnson & Johnson (NYSE:JNJ) have said they plan to tell Indian officials […]